Novo Nordisk News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

24.06.24	Novo Nordisk Reports Superiority Of Mim8 Prophylaxis In Hemophilia A Trial (RTTNews)
21.06.24	MÄRKTE EUROPA/Schwach nach Verfall - Tech- und Bankwerte belasten (Dow Jones)
21.06.24	The Best Could Be Yet to Come for Novo Nordisk and Ozempic (MotleyFool)
17.06.24	Novo Nordisk CEO Agrees To Testify In US Senate Hearing Over Ozempic, Wegovy Prices (RTTNews)
13.06.24	Novo Nordisk Unusual Options Activity For June 13 (Benzinga)
12.06.24	Ozempic Maker Novo Nordisk Closes In On Lego As Denmark's Most Valuable Brand: Report (Benzinga)
10.06.24	6 Analysts Have This To Say About Novo Nordisk (Benzinga)
06.06.24	Ozempic Just Got Even More Bullish For Novo Nordisk Stock, Yet Again (MotleyFool)
06.06.24	Chinese Generic Ozempic, Wegovy Versions Could Put Novo Nordisk At The Risk Of Stiff Competition In Key Market (Benzinga)
04.06.24	Here Are 3 More Reasons to Be Bullish on Ozempic and Novo Nordisk Stock (MotleyFool)
03.06.24	$100 Invested In Novo Nordisk 10 Years Ago Would Be Worth This Much Today (Benzinga)
01.06.24	This Is the Biggest Risk for Eli Lilly and Novo Nordisk Investors (MotleyFool)
31.05.24	Novo Nordisk Sues Additional US Clinics Against Fake Semaglutide Products Used For Weight Loss, Diabetes (Benzinga)
30.05.24	New Weight Loss ETF Is Essentially A Play On Eli Lilly, Novo Nordisk (Benzinga)
30.05.24	Weight Loss Drug Market To Rocket To $130B By 2030 With Eli Lilly, Novo Nordisk In Lead: Goldman Sachs (Benzinga)
29.05.24	Weight-Loss Drug Forecasts Skyrocket To $150B As Novo Nordisk, Eli Lilly Ramp Up Supply (Benzinga)
28.05.24	Novo Nordisk Faces Scrutiny Over High Prices of Ozempic And Wegovy, Blames US Health System (Benzinga)
28.05.24	Novo Nordisk blames middlemen in U.S. healthcare system for high prices of weight loss drugs Wegovy and Ozempic (MarketWatch)
26.05.24	Amgen's Catching Up to Novo Nordisk and Eli Lilly. Should You Buy It? (MotleyFool)
25.05.24	Where Will Novo Nordisk Be in 10 Years? (MotleyFool)
25.05.24	Novo-Nordisk-Chef Jørgensen kritisiert „naive Regulierung“ in Europa (WELT)
24.05.24	Study Says Novo Nordisk's Ozempic Reduces Kidney Disease Risks (RTTNews)
24.05.24	Novo Nordisk Releases Data Showing Ozempic For Diabetes Slows Kidney Disease Progression (Benzinga)
22.05.24	Australia Bans Replica Versions Of Popular Weight-Loss Drugs From Novo Nordisk, Eli Lilly On Safety Concerns (Benzinga)
22.05.24	Novo Nordisk-Aktie gibt ab: Feuer in Novo Nordisks Zentrale (Dow Jones) Bei dem Pharmahersteller Novo Nordisk brennt es schon wieder.» mehr
18.05.24	Is Novo Nordisk Stock a Millionaire Maker? (MotleyFool)
17.05.24	Meet the GLP-1 Drug That Could Be the Biggest Concern for Eli Lilly and Novo Nordisk (MotleyFool)
16.05.24	Here's How Much You Would Have Made Owning Novo Nordisk Stock In The Last 10 Years (Benzinga)
16.05.24	MÄRKTE EUROPA/Konsolidierungstag - Siemens nach Zahlen unter Druck (Dow Jones)
16.05.24	Novo Nordisk Building Site Hit By Fire (RTTNews)
15.05.24	No Wegovy Shortage in Denmark Amid High Demand, Novo Nordisk Confirms (Benzinga)
15.05.24	If You'd Invested $1,000 in Novo Nordisk Stock 5 Years Ago, Here's How Much You'd Have Today (MotleyFool)
15.05.24	Novo Nordisk Bets Up to $600 Million on Ozempic 2.0. Here's Why the Stock Is a Buy. (MotleyFool)
14.05.24	Novo Nordisk to test weight-loss drugs’ effect on alcohol use and liver disease (Financial Times)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Part Grp Hldg	1’263.50	2.89 %	K V
Sonova Hldg	312.10	2.66 %	K V
Novartis	93.68	2.32 %	K V
Geberit	526.80	1.97 %	K V
Roche Hldg G	254.30	1.27 %	K V
Kuehne+Nagel Int	209.50	0.72 %	K V
UBS Group	28.30	0.57 %	K V
Givaudan	3’933.00	0.36 %	K V
Nestle	76.00	0.05 %	K V
Lonza Grp	521.40	-0.04 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu Novo Nordisk (spons. ADRs)

Aktien Top/Flop

Novo Nordisk Peer Group Nachrichten

Meistgelesene Nachrichten